S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Sell every Stock except ONE (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
AP source: Biden, McCarthy reach final deal to prevent default, now must sell to Congress
Sell every Stock except ONE (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Sell every Stock except ONE (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Forecast, Price & News

$16.42
+0.11 (+0.67%)
(As of 05/26/2023 ET)
Compare
Today's Range
$16.12
$16.48
50-Day Range
$15.65
$22.89
52-Week Range
$14.51
$29.14
Volume
424,202 shs
Average Volume
1.79 million shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.85

Travere Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
81.8% Upside
$29.85 Price Target
Short Interest
Bearish
10.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Travere Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$29,478 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.63) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

406th out of 1,012 stocks

Pharmaceutical Preparations Industry

185th out of 495 stocks


TVTX stock logo

About Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
11 Analysts Have This to Say About Travere Therapeutics
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Travere Therapeutics (NASDAQ:TVTX) PT Lowered to $22.00
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Company Calendar

Last Earnings
10/28/2021
Today
5/28/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TVTX
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.85
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+81.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-278,480,000.00
Net Margins
-130.98%
Pretax Margin
-130.83%

Debt

Sales & Book Value

Annual Sales
$212.02 million
Book Value
$2.54 per share

Miscellaneous

Free Float
71,810,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
0.46

Key Executives

  • Eric M. DubeEric M. Dube
    President, Chief Executive Officer & Director
  • Chris Cline
    Chief Financial Officer
  • Bill Rote
    Senior VP, Head-Research & Development
  • Jula Inrig
    Chief Medical Officer
  • Elizabeth E. ReedElizabeth E. Reed
    Secretary, Senior Vice President & General Counsel













TVTX Stock - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price forecast for 2023?

11 equities research analysts have issued 12-month price targets for Travere Therapeutics' shares. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they anticipate the company's share price to reach $29.85 in the next twelve months. This suggests a possible upside of 81.8% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2023?

Travere Therapeutics' stock was trading at $21.03 at the beginning of 2023. Since then, TVTX shares have decreased by 21.9% and is now trading at $16.42.
View the best growth stocks for 2023 here
.

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our TVTX earnings forecast
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) posted its quarterly earnings data on Thursday, October, 28th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.13. The business earned $68.20 million during the quarter, compared to analysts' expectations of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 236.09% and a negative net margin of 130.98%. The firm's revenue was up 33.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.44) earnings per share.

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.58%), State Street Corp (5.85%), Macquarie Group Ltd. (4.89%), Renaissance Technologies LLC (2.87%), Assenagon Asset Management S.A. (2.23%) and Pictet Asset Management SA (2.08%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends
.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $16.42.

How much money does Travere Therapeutics make?

Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.23 billion and generates $212.02 million in revenue each year. The company earns $-278,480,000.00 in net income (profit) each year or ($4.44) on an earnings per share basis.

How many employees does Travere Therapeutics have?

The company employs 310 workers across the globe.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280.

This page (NASDAQ:TVTX) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -